To conclude, by using the Gleason score information supplemented with the expression of FMOD and PTPN2 genes, a stratification of prostate cancer patients into several prognostic subgroups with significantly different hazard ratios (low, medium, and high risk of progression) was achieved. This evidence concerns the gene PTPN2 and prostate carcinoma.